Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia.
Point mutations of the N-ras oncogene are relatively common in acute myelogenous leukemia (AML) cells, occurring in some 25% to 50% of patient samples. We used a technique involving the direct nucleotide sequencing of in vitro amplified N-ras genomic fragments to determine the frequency of N-ras point mutations in chronic myeloid leukemia (CML) cells at various stages of the disease. This approach will detect N-ras point mutations in a mixed population of cells if the mutation is present in 25% or more of the cells. We could not demonstrate any point mutation at N-ras codons 12,13 or 59-63 in any of the 44 CML cases analyzed, which included 21 blast crisis samples. In contrast with AML N-ras point mutations are exceedingly rare in CML.
Collins
S J
SJ
Molecular Medicine Program, Fred Hutchinson Cancer Research Center, Seattle 98104.
Howard
M
M
Andrews
D F
DF
Agura
E
E
Radich
J
J
D015321:Gene Rearrangement; D011905:Genes, ras; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D009154:Mutation; D010677:Philadelphia Chromosome